Closing Market Summary: S&P 500 Records First Loss Since December 1The S&P 500 (-0.1%) began the week with a modest downtick to register its first decline in seven sessions. The Nasdaq Composite (-0.6%) underperformed while the Dow Jones Industrial Average (+0.2%) eked out a slim gain.
The new trading week was headlined by news from Vienna, where non-OPEC producers agreed to reduce their output by 558,000 barrels per day. In addition, a Saudi official indicated that his country may implement a larger cut than what was agreed to on November 30. Crude oil surged on the news, notching an overnight high near $54.50/bbl. The energy component pulled back throughout the day, ending its pit session with a 2.6% gain at $52.83/bbl.
Crude oil's surge gave a boost to the energy sector (+0.7%), but the group spent the day in a steady slide from its opening high after being up more than 2.0%. However, energy still fared better than the remaining five cyclical sectors, considering all five spent the day in negative territory.
The industrial sector (-0.4%) was pressured by defense contractors after President-elect Donald Trump criticized another defense contract he deemed excessive. Mr. Trump took aim at the F-35 program, sending shares of aircraft manufacturer Lockheed Martin (LMT 253.22, -6.30) lower by 2.4%. Most defense contractors retreated in sympathy with Lockheed Martin while Boeing (BA 157.16, +0.67) edged up to its record high. The Dow component has climbed 3.3% since being called out by Mr. Trump last Wednesday.
Similar to industrials, consumer discretionary (-0.8%), financials (-0.9%), and technology (-0.4%) spent the day in negative territory. Apparel retailers weighed on the discretionary space while the financial sector pulled back after last week's run. As for technology, the top-weighted group saw losses among large cap names and high-beta chipmakers. The PHLX Semiconductor Index lost 0.8% with Micron (MU 20.01, -0.49) falling 2.4% after the company warned that the memory market may be flooded by China within a few years.
The technology sector contributed to the relative weakness in the Nasdaq, but biotechnology also weighed on the tech-heavy index. The iShares Nasdaq Biotechnology ETF (IBB 267.53, -2.14) settled lower by 0.8% with Alexion Pharmaceuticals (ALXN 115.08, -16.99) diving 12.9% after two top executives resigned from the company.
Unlike biotechnology, the broader health care sector (+0.5%) held a modest gain throughout the session. Other countercyclical groups also displayed relative strength with telecom services (+1.1%) and utilities (+1.0%) ending in the lead.
Treasuries retreated overnight, but most of the losses were erased intraday, leaving the 10-yr yield higher by a basis point at 2.48%.
Investor participation was above average as nearly 1.2 billion shares changed hands at the NYSE floor.
Today's economic data was limited to the Treasury Budget statement for November, which showed a deficit of $137 billion while the consensus expected a deficit of $135 billion.
Tomorrow's economic data will be limited to the 8:30 ET release of November Import Prices ex-oil and Export Prices ex-agriculture.
- Russell 2000 +21.5% YTD
- Dow Jones Industrial Average +13.6% YTD
- S&P 500 +10.4% YTD
- Nasdaq Composite +8.1% YTD
- According to LMT's latest 10K "Our Aeronautics business segment includes our largest program, the F-35 Lightning II Joint Strike Fighter, an international multi-role, multi-variant, stealth fighter aircraft. Net sales for the F-35 program represented approximately 23% of our total consolidated net sales from continuing operations for both the quarter and nine months ended September 25, 2016 and 23% of our total consolidated net sales from continuing operations for both the quarter and nine months ended September 27, 2015.
- Defense names: LMT -2.6%, RTN -1.5%, NOC -1.4%, GD -1.4%, BA -0.6%, LLL
In reaction to disappointing earnings/guidance:
- OPTT -6.6%
- OPHT -81.8% (reports Phase 3 results for Fovista; No benefit observed upon addition of Fovista to monthly Lucentis regimen)
- ALXN -13.2% (names David Brennan as Interim CEO effective immediately; new CFO also named; update on audit investigation provided)
- PTI -8.8% (receives notice of termination from Biogen (BIIB) relating to their collaborative research, development, commercialization and license agreement)
- CNI -2.5% (cautious report from SIRF)
- OTEX -1.9% (launches an underwritten public offering of $500 mln of common shares )
- BIDU -1.1% (in sympathy with Shanghai down 2.5% overnight)
- GFI -1.4% (downgraded to Sector Perform at RBC Capital Mkts)
- MDXG -1.4% (initiated with a Sell at UBS)
In reaction to strong earnings/guidance:
- LITB +5.3%, JOUT +1.0%
- CSOD +6.7% (has received interest from buyers, according to Bloomberg)
- MTL +16.7%, BBL +5.1%, BHP +4.4%, MT +2.2%, CLF +1.9%, FCX +1.2%, RIO +1.2%
- PACD +22%, SDRL +17.3%, CRC +12.4%, OAS +9.1%, BTE +9.1%, WLL +8.6%, LPI +8.6%, MRO +7.1%, RIG +7.1%,WFT +7%, ESV +6.7%, SSL +6.5%
- CHK +5.6%, HOS +5%, BBG +4.3%, COP +4%, STO +2.8%, YNDX +2.7%, RDS.A +2.6%, BP +2.4%, SWN +2.4%, SLB+2%, TOT +1.9%, XOM +1.6%, CVX +1.5%
- AKAO +53.3% (announces positive results in Phase 3 cUTI and CRE clinical trials of Plazomicin)
- SGY +18% (announces extensions to restructuring support agreement, purchase and sale agreement and credit agreement)
- ATW +9.8% (continued strength in the shipping space)
- NE +7.3% (Noble Corp PLC and certain subsidiaries of Royal Dutch Shell plc (RDS.A) have agreed to amend the existing long-term contracts on three ultra-deepwater drillship)
- PHMD +5.2% (continued strength)
- AXON +1.8% (presented new data analysis showing addition of intepirdine to standard therapy may help people with Alzheimer's Disease maintain independence longer)
- REGN +4.6% (upgraded to Neutral at Chardan Capital Markets)
- AMD +1.7% (upgraded to Outperform from Market Perform at BMO Capital)
- ABB +1.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- FMC +1.1% (upgraded to Buy from Neutral at Goldman)